Experience Fast Relief with Abreva UK Cold Sore Treatment Cream

Say goodbye to the uncomfortable pain of cold sores with Abreva UK Cold Sore Treatment Cream.

With its powerful formula containing 10% docosanol, this cream offers fast relief by addressing your cold sore right at its source. The moment you feel that first tingle, you can trust Abreva to significantly reduce the duration of your cold sore experience.

An outbreak can derail your day, but with Abreva, you don't have to let it. This effective cold sore treatment works deep to create a protective barrier around healthy skin cells, which not only alleviates tingling, pain, burning, and itching but also prevents the spread of the herpes simplex virus type 1 (HSV-1). What's more, it is the only FDA-approved non-prescription treatment that can accelerate healing to as little as 2 1/2 days when applied promptly!

Key Highlights of Abreva Cold Sore Treatment

• Quick-acting treatment in a convenient 0.07 oz tube.
• Formulated with 10% docosanol to effectively shorten cold sore symptoms.
• Pierces deep to tackle cold sores at their origin.
• Lessens discomfort caused by tingling, pain, burning, and itching.
• Easy to apply and ideal for on-the-go relief.
• FDA-approved for speeding up healing time—one of the best cold sore remedies out there!

Don’t let cold sores hold you back; invest in your comfort and confidence today with Abreva UK Cold Sore Treatment Cream. Add it to your cart now for fast relief when you need it most!

Directions

Adults and children 12 years or over: Wash hands before and after applying cream. Apply to affected area on face or lips at the first sign of cold sore/fever blister (tingle). Early treatment ensures the best results. Rub in gently but completely. Use 5 times a day until healed. Children under 12 years: Ask a doctor.

Ingredients

Active Ingredients: Docosanol 10% - Cold sore/fever blister treatment; Inactive Ingredients: Benzyl alcohol, light mineral oil, propylene glycol, purified water, sucrose distearate, sucrose stearate.